A First-in-Human Study of CD123 Natural Killer Cell Engager (NKCE) SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-Myelodysplasia (HR-MDS)

被引：0
|
作者：
Stein, Anthony [1 ]
Lavrencic, Mojca [2 ]
Garciaz, Sylvain [3 ]
Huls, Gerwin [4 ]
Maiti, Abhishek [5 ]
Boissel, Nicolas [6 ]
Botton, Stephane [7 ]
Fleming, Shaun [8 ]
Zwaan, Michel [9 ]
de Leeuw, David C. [10 ]
Desai, Pinkal [11 ]
Arellano, Martha [12 ]
Avigan, David [13 ]
Langemeijer, Saskia [14 ]
Jensen, Kyle [15 ]
Wagenaar, Timothy [15 ]
Mi Gu [15 ]
Abbadessa, Giovanni [15 ]
Bajel, Ashish [16 ,17 ]
机构：
[1] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[3] Aix Marseille Univ, Inst Paoli Calmettes, Marseille, France
[4] Univ Med Ctr Groningen, Groningen, Netherlands
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Hop St Louis, Paris, France
[7] Inst Gustave Roussy, Paris, France
[8] Alfred Hlth, Melbourne, Vic, Australia
[9] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[10] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[11] Weill Cornell Med, New York, NY USA
[12] Emory Univ, Atlanta, GA 30322 USA
[13] Beth Israel Deaconess Med Ctr, Boston, MA USA
[14] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
[15] Sanofi, Cambridge, MA USA
[16] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[17] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-002
引用
收藏
页码：S3 / S4
页数：2
相关论文
共 50 条
  • [1] Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute myeloid leukemia (R/R AML), B cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)
    Jongen-Lavrencic, M.
    Bajel, A.
    Garciaz, S.
    Maiti, A.
    Fleming, S.
    De Button, S.
    Huls, G. A.
    Jensen, K.
    Ziti-Ljajic, S.
    Draganov, D.
    Rotolo, F.
    Palu, C.
    Courta, J.
    Passe-Coutrin, W.
    Traudtner, K.
    Wagenaar, T.
    Abbadessa, G.
    Stein, A. Selwyn
    ANNALS OF ONCOLOGY, 2023, 34 : S543 - S544
  • [2] A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
    Stein, Anthony Selwyn
    Jongen-Lavrencic, Mojca
    Garciaz, Sylvain
    Huls, Gerwin A.
    Maiti, Abhishek
    Boissel, Nicolas
    De Botton, Stephane
    Fleming, Shaun
    Zwaan, C. Michel
    de Leeuw, David C.
    Desai, Pinkal
    Arellano, Martha Lucia
    Avigan, David
    Langemeijer, Saskia
    Jensen, Kyle A.
    Wagenaar, Timothy
    Mi, Gu
    Abbadessa, Giovanni
    Bajel, Ashish
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
    Stein, Anthony S.
    Bajel, Ashish
    Fleming, Shaun
    Jongen-Lavrencic, Mojca
    Garciaz, Sylvain
    Maiti, Abhishek
    Boissel, Nicolas
    De Botton, Stephane
    Huls, Gerwin A.
    de Leeuw, David C.
    Avigan, David
    Jensen, Kyle
    Demers, Brigitte
    Wagenaar, Timothy
    Mi, Gu
    Ziti-Ljajic, Samira
    Draganov, Dobrin
    Abbadessa, Giovanni
    Wei, Andrew H.
    BLOOD, 2022, 140 : 7476 - 7477
  • [4] First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High RiskMyelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics
    Bajel, Ashish
    Garciaz, Sylvain
    Desai, Pinkal
    Huls, Gerwin A.
    Maiti, Abhishek
    Jongen-Lavrencic, Mojca
    Boissel, Nicolas
    De Botton, Stephane
    de Leeuw, David C.
    Fleming, Shaun
    Zwaan, C. Michel
    Arellano, Martha
    Avigan, David
    Saultz, Jennifer N.
    Mantzaris, Ioannis
    Jensen, Kyle
    Wagenaar, Timothy
    Mi, Gu
    Ziti-Ljajic, Samira
    Draganov, Dobrin
    Abbadessa, Giovanni
    Stein, Anthony Selwyn
    BLOOD, 2023, 142
  • [5] Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
    Mueller, Karen Thudium
    Grupp, Stephan A.
    Maude, Shannon L.
    Levine, John E.
    Pulsipher, Michael
    Boyer, Michael W.
    August, Keith Jason
    Myers, Gary Douglas
    Awasthi, Rakesh
    Waldron, Edward K.
    Bubuteishvili-Pacaud, Lida
    Taran, Tanya
    Cota, Mariana
    Tam, Constantine Si Lun
    Jager, Ulrich
    Foley, Ronan
    Borchmann, Peter
    Schuster, Stephen J.
    Waller, Edmund K.
    Laetsch, Theodore Willis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Real World Treatment of Pediatric Patients with Down Syndrome and Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-All) Treated with Tisagenlecleucel
    Pacenta, H.
    Schultz, L.
    Baggott, C.
    Shah, N.
    Prabhu, S.
    Phillips, C.
    Rossoff, J.
    Stefanski, H.
    Talano, J. -A.
    Moskop, A.
    Margossian, S.
    Verneris, M.
    Myers, G.
    Karras, N.
    Brown, P.
    Qayed, M.
    Hermiston, M.
    Satwani, P.
    Krupski, C.
    Keating, A.
    Wilcox, R.
    Rabik, C.
    Fabrizio, V.
    Rouce, R.
    Chinnabhandar, V.
    Kunicki, M.
    Barsan, V.
    Goksenin, A.
    Curran, K.
    Mackall, C.
    Laetsch, T.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S87 - S88
  • [7] Sinusoidal Obstruction Syndrome in Patients with Relapsed/Refractory (R/R) b-cell Acute Lymphoblastic Leukemia (B-all) Treated with ari-0001 Cells
    Ortiz-Maldonado, Valentin
    Alonso-Saladrigues, Anna
    Caballero-Banos, Miguel
    Castella, Maria
    Boronat, Anna
    Garcia-Rey, Enric
    Baumann, Tycho
    Diaz-Beya, Marina
    Torrebadell, Montserrat
    Faura, Anna
    Catala, Albert
    Ramos, Federico
    Palomino, Alicia
    Gomez-Hernando, Marta
    Jimenez-Vicente, Carlos
    Cid, Joan
    Lozano, Miquel
    Llanos, Cristina
    Tellez, Adrian
    Fernandez, Sara
    Castro, Pedro
    Jordan, Iolanda
    Esteve, Jordi
    Maria Canals, Josep
    Trias, Esteve
    Yague, Jordi
    Suarez-Lledo, Maria
    Rovira, Montserrat
    Urbano-Izpizua, Alvaro
    Juan, Manel
    Rives, Susana
    Delgado, Julio
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 235 - 236
  • [8] CNCT19 for Treatment of Patients with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-cell ALL) in Children and Adults
    Wang, Ying
    Chen, Xiaojuan
    Wei, Shuning
    Mi, Yingchang
    Shi, Lin
    Wang, Ying
    Wang, Yongzeng
    Haudenschild, Changting
    Lv, Lulu
    Zhu, Xiaofan
    Wang, Jianxiang
    BLOOD, 2021, 138
  • [9] Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
    Li, Shiqi
    Wang, Xinxin
    Yuan, Zhongtao
    Liu, Lin
    Li, Yu
    Liu, Jia
    He, Jiaping
    Li, Zhimin
    Zhao, Wei
    Ge, Jianning
    Ni, Yajin
    Shen, Lianjun
    Cao, Wei
    Zhang, Xi
    Sersch, Martina
    Wang, Sanbin
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
    Martinez Sanchez, Pilar
    Gordon, Paul
    Schwartz, Stefan
    Rossi, Giuseppe
    Huguet, Francoise
    Maria Hernandez-Rivas, Jesus
    Kadu, Priti
    Wong, Hansen L.
    Markovic, Ana
    Katlinskaya, Yuliya
    Panwar, Bharat
    Zugmaier, Gerhard
    BLOOD, 2021, 138
12345